# Autonomous Dossier Structuring for Pharma

*/Opportunities/Autonomous_Dossier_Structuring_for_Pharma*

## Opportunity Overview

**Wedge**: The beachhead targets Investigational New Drug (IND) applications for Phase 1 oncology trials. Oncology represents the highest volume of new clinical pipelines, and INDs are narrower in scope than full NDAs, enabling rapid, provable deployment. From this initial insertion, the capability expands into Phase 2/3 clinical study reports, Chemistry, Manufacturing, and Controls (CMC) modules, and ultimately full New Drug Application (NDA) assemblies.
**Timing**: Long-context LLMs now ingest and synthesize 100+ page clinical study reports and manufacturing manuals without the data loss previously caused by chunking. Simultaneously, global regulators are enforcing the eCTD v4.0 standard, forcing sponsors to execute mass migrations and re-structuring of legacy trial data.
**Why This I C P**: Mid-market, clinical-stage biopharma sponsors lack the massive internal regulatory affairs departments of top-tier pharmaceutical giants. They currently overpay CROs for basic document formatting and feel immediate margin pressure, making them highly motivated buyers for systems that directly replace submission preparation costs.
**Size Of Prize**: Approximately 5,000 clinical-stage biopharma sponsors spend an average of $200,000 annually on external regulatory publishing and structuring services per active asset. This yields a $1B total addressable prize captured directly from legacy consultancy and CRO spend.
**Gap Narrative**: Pharmaceutical regulatory teams assemble thousands of trial documents, legacy datasets, and manufacturing reports into strict eCTD submission formats manually or via costly consultants. Existing systems act as simple document repositories but fail to parse and map raw content into these complex regulatory hierarchies. This leaves a gap for a system that autonomously extracts unstructured data and structures it directly into compliant submission dossiers.
**Defensibility**: Defensibility compounds through workflow lock-in and historical data mapping. Once the system processes an initial IND, it retains the proprietary semantic mapping of that asset's entire data architecture. Transitioning to a competitor for subsequent Phase 2 updates or the final NDA requires abandoning this historical context, creating massive switching costs for the sponsor.
**Why This Thesis**: Service-as-Software matches the existing purchasing behavior of clinical sponsors who already outsource regulatory publishing as an end-to-end service. Delivering a completed, structured dossier replaces their existing CRO contract directly, avoiding the friction of forcing lean scientific teams to learn and operate a new SaaS tool.

## Opportunity Linked Thesis

**Thesis**: [Agent](/Theses/Agent)

## Opportunity Linked I C P

**Icp**: [Pharmaceutical Company](/CompanyTypes/Pharmaceutical_Company)

## Opportunity Market Sizing

_Illustrative — target and order-of-magnitude estimate figures, not an achieved track record (this Thing is concept-stage)._

**S A M**: ~$400M - $600M targeting US and EU mid-to-large pharmaceutical companies actively submitting complex NDAs and BLAs
**S O M**: ~$20M - $40M realistic 3-year capture targeting the top 500 well-funded US biotechs and mid-market pharma
**T A M**: ~10,000 global clinical-stage biopharma sponsors × ~$150k/yr average regulatory structuring spend ≈ ~$1.5B
**Growth Rate**: ~12-18%/yr, driven by rising clinical trial volumes, complex biologics filings, and stricter global eCTD formatting mandates
**Paid Comparable Spend**: ~$100k - $300k+ per major submission spent on outsourced medical writing agencies, CROs, and manual regulatory operations labor

## Opportunity Incumbents

- [Veeva Vault Submissions](/Products/Veeva_Vault_Submissions) — Tool
- [LORENZ docuBridge](/Products/LORENZ_docuBridge) — Tool
- [Certara GlobalSubmit](/Products/Certara_GlobalSubmit) — Tool
- [Parexel Regulatory Outsourcing](/Products/Parexel_Regulatory_Outsourcing) — Service
- [Extedo eCTDmanager](/Products/Extedo_eCTDmanager) — Tool
- [In-House Word Macros](/Products/In-House_Word_Macros) — DIY
- [Excel Tracking Matrices](/Products/Excel_Tracking_Matrices) — Spreadsheet

## Opportunity Win Conditions

**Kill Thresholds**:
- Manual QA time exceeds 1 hour per 50 pages of ingested raw documents after 60 days
- Zero IT or security vendor approvals secured within the first 90 days of targeted outreach
- Pilot-to-paid conversion is < 20% after a completed filing pilot
- Sales cycles consistently exceed 180 days for mid-market biopharma targets
**Leading Metrics**:
- Time-to-first-structured-eCTD-module
- Percentage of automated document-to-node mappings accepted without manual edits
- Human-in-the-loop QA time per 100 pages ingested
- Number of raw clinical documents processed per active user per week
- Security and IT approval pipeline velocity in days
**What Proves Right**: Regulatory affairs teams automatically map raw clinical narratives into compliant eCTD module structures with less than 10% manual rework. Initial mid-market pharma cohorts sign $50k+ annual contracts after completing a single BLA or NDA pilot submission. Users ingest new trial data directly into the system rather than exporting raw files to external CRO medical writers.
**What Proves Wrong**: The system fails to consistently parse heterogeneous CRO document formats, forcing regulatory teams to spend more time performing QA than they would writing from scratch. Compliance and IT departments block adoption outright due to a strict mandate to only use Veeva Vault for submission-critical workflows. The sales cycle drags beyond 9 months because sponsors refuse to risk their NDA timelines on unproven structuring software.

## Opportunity Build Profile

**Hardest Part**: Maintaining strict data provenance while extracting hierarchically nested tables from raw clinical reports into rigid regulatory schemas. A single misplaced decimal or hallucinated unit in a pharmacokinetic table triggers immediate submission rejection.
**Min Viable Scope**: Scope v1 exclusively to structuring Module 3 (Quality/CMC) for initial Investigational New Drug applications. Deliberately exclude final eCTD XML gateway publishing, non-US regional formats, and full-scale NDA cross-module hyperlinking.
**Cold Start Problem**: Pharma sponsors refuse to provide highly confidential, pre-submission intellectual property to unproven vendors for model training. Break this by scraping decades of publicly available FDA review packages and FOIA-released clinical study reports to build the baseline extraction engine.
**Time To First Value**: 2–4 weeks to map the sponsor's custom source templates and generate the first fully traceable draft of a single dossier module
**Data Moat Available**: true
**Technical Difficulty**: High

## Neighborhood

### Incumbent in

- [In-House VBA Macros](/Products/In-House_VBA_Macros) — incumbent in · Products
- [Excel Traceability Matrices](/Products/Excel_Traceability_Matrices) — incumbent in · Products
- [Lorenz DocuBridge](/Products/Lorenz_DocuBridge) — incumbent in · Products
- [Veeva Vault Submissions](/Products/Veeva_Vault_Submissions) — incumbent in · Products
- [Certara GlobalSubmit](/Products/Certara_GlobalSubmit) — incumbent in · Products
- [Extedo eCTDmanager](/Products/Extedo_eCTDmanager) — incumbent in · Products
- [Parexel Regulatory Outsourcing](/Products/Parexel_Regulatory_Outsourcing) — incumbent in · Products

### Applies thesis

- [Pharmaceutical Company](/CompanyTypes/Pharmaceutical_Company) — applies thesis · CompanyTypes

### Embodies

- [Agent](/Theses/Agent) — embodies · Theses

### Similar Opportunities

- [Clinical Trial Artifact Parsing](/Opportunities/Clinical_Trial_Artifact_Parsing) — similar · Opportunities
- [Autonomous Dossier Compilation for Hardware](/Opportunities/Autonomous_Dossier_Compilation_for_Hardware) — similar · Opportunities
- [IRB Proxy](/Opportunities/IRB_Proxy) — similar · Opportunities
- [Revision Pipeline Manager](/Opportunities/Revision_Pipeline_Manager) — similar · Opportunities
- [Certification Dossier Service](/Opportunities/Certification_Dossier_Service) — similar · Opportunities
- [Toxicology Reporting Service](/Opportunities/Toxicology_Reporting_Service) — similar · Opportunities
- [Clinical Evidence Compiler](/Opportunities/Clinical_Evidence_Compiler) — similar · Opportunities
- [IRB Protocol Preparation](/Opportunities/IRB_Protocol_Preparation) — similar · Opportunities
- [Regulatory Standard Mapping for MedTech](/Opportunities/Regulatory_Standard_Mapping_for_MedTech) — similar · Opportunities
- [Synthetic Mock Site Visits](/Opportunities/Synthetic_Mock_Site_Visits) — similar · Opportunities
- [Launch Compliance Agent](/Opportunities/Launch_Compliance_Agent) — similar · Opportunities
- [Certification Dossier Service](/Knowledge/Engineering_and_Technology/Opportunities/Certification_Dossier_Service) — similar · Opportunities
- [Automated Proposal Writer](/CompanyTypes/Engineering_Contract_Research_Organizations_(CROs)/Opportunities/Automated_Proposal_Writer) — similar · Opportunities
- [Managed Validation Service](/Metrics/Requirements_Traceability_Index/Processes/Verification_And_Validation/Opportunities/Managed_Validation_Service) — similar · Opportunities
- [Hazmat Compliance Automation](/Opportunities/Hazmat_Compliance_Automation) — similar · Opportunities
- [Protocol Compliance Agent](/Opportunities/Protocol_Compliance_Agent) — similar · Opportunities
- [NRC Filing Service](/Opportunities/NRC_Filing_Service) — similar · Opportunities
- [Certification Audit Service](/Metrics/Requirements_Traceability_Index/Opportunities/Certification_Audit_Service) — similar · Opportunities
- [Compliance Reporting Automation](/Opportunities/Compliance_Reporting_Automation) — similar · Opportunities
- [Critical Requirement Gating](/Metrics/Requirements_Traceability_Index/Processes/Software_Testing/Opportunities/Critical_Requirement_Gating) — similar · Opportunities